Accenture consultants Jeff Elton and Anne O’Riordan argue that coming changes in health care should benefit patients and humanity at large. They assert that drug companies and device makers will come to pursue business models that profit from curing people, not from pushing pills. Their enthusiasm is enviable, although their writing style can be turgid. If you’re not already versed in health care, you also may have a hard time with their insider argot. And Trump administration changes in Obamacare could outdate some of their overview. While always politically neutral, getAbstract suggests this thought-provoking study to health professionals, patients and investors.
In this summary, you will learn
- How changes in health care also change patient care and economic models,
- How giants such as Novartis adapt, and
- How health care will change in the future.
About the Authors
Jeff Elton, managing director of Accenture Strategy, has founded several health care companies. Anne O’Riordan is global industry senior managing director of Accenture Life Sciences.
Comment on this summary
Contained in Knowledge Pack:
Knowledge PackLife SciencesHere’s an X-ray view.
Customers who read this summary also read
Esmé E. Deprez and Paul Barrett
Bloomberg Businessweek , 2017